Cortiderm-NN (clobetasol propionate + neomycin + nystatin): Uses, Dosage & Side Effects

What it's for (Indications)

This combination topical medication is indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, such as eczema, psoriasis, and various forms of dermatitis, where secondary bacterial and/or fungal infections are present, suspected, or likely to occur.
The clobetasol propionate component addresses the inflammatory and pruritic symptoms, while neomycin targets susceptible bacterial pathogens, and nystatin is effective against Candida species.
This formulation is particularly useful for conditions where a mixed infection is contributing to the dermatological presentation, offering a comprehensive approach to managing complex skin conditions by simultaneously combating inflammation and microbial proliferation.
It should be reserved for short-term use due to the high potency of the corticosteroid component.

Dosage Information

Type	Guideline
Standard	A thin layer of the cream or ointment should be applied to the affected skin area, typically two to three times daily, or as directed by a healthcare professional. The duration of treatment should be limited, generally not exceeding two consecutive weeks, particularly on facial areas, intertriginous zones (e.g., groin, axillae), and in pediatric patients, due to the high potency of clobetasol propionate and the risk of systemic absorption. The total dosage should not exceed 50 grams per week. Occlusive dressings are generally discouraged as they significantly increase the systemic absorption of clobetasol propionate, escalating the risk of adverse effects. Exact frequency and duration must be tailored by the prescribing physician based on the severity of the condition, the patient's age, and the specific body area being treated, with careful monitoring for both local and systemic adverse reactions.

Type

Guideline

Standard

A thin layer of the cream or ointment should be applied to the affected skin area, typically two to three times daily, or as directed by a healthcare professional. The duration of treatment should be limited, generally not exceeding two consecutive weeks, particularly on facial areas, intertriginous zones (e.g., groin, axillae), and in pediatric patients, due to the high potency of clobetasol propionate and the risk of systemic absorption. The total dosage should not exceed 50 grams per week. Occlusive dressings are generally discouraged as they significantly increase the systemic absorption of clobetasol propionate, escalating the risk of adverse effects. Exact frequency and duration must be tailored by the prescribing physician based on the severity of the condition, the patient's age, and the specific body area being treated, with careful monitoring for both local and systemic adverse reactions.

Safety & Warnings

Common Side Effects

Due to the potent corticosteroid component, clobetasol propionate, potential local side effects include burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.
Systemic absorption of clobetasol, especially with prolonged use, extensive surface area application, or occlusive dressings, can lead to more serious effects such as Cushing's syndrome, hyperglycemia, and glucosuria, as well as hypothalamic-pituitary-adrenal (HPA) axis suppression.
The neomycin component can cause local irritation, sensitization (allergic contact dermatitis), and in rare cases with significant systemic absorption, ototoxicity and nephrotoxicity.
Nystatin is generally well-tolerated topically, with rare reports of irritation.
Any persistent or severe side effects, or signs of systemic absorption, should prompt immediate medical evaluation.

Serious Warnings

Black Box Warning: While Clobetasol Propionate alone, and typically combination products containing it, do not carry a formal FDA 'Black Box Warning' like some systemic medications, the high potency of clobetasol propionate necessitates a critical 'Serious Warnings' section due to the potential for significant adverse effects. **Serious Warnings**: **1. Systemic Absorption and Adrenal Suppression**: Clobetasol propionate is a highly potent topical corticosteroid. Prolonged use, application to large surface areas, use under occlusive dressings, or use in children can lead to significant systemic absorption. This can result in hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria. Pediatric patients may be more susceptible to systemic toxicity due to their larger skin surface area to body weight ratio. Adrenal function should be assessed periodically, and the product should be discontinued if HPA axis suppression is confirmed. **2. Local Adverse Reactions**: Long-term application or use in sensitive areas (e.g., face, intertriginous areas, thin skin) can lead to irreversible local adverse reactions, including skin atrophy, striae, telangiectasias, and perioral dermatitis. **3. Infection Masking**: The corticosteroid component can mask the clinical signs of existing infection, potentially delaying diagnosis and appropriate treatment, or exacerbating the infection if the antimicrobial components are ineffective against the causative organism. If irritation or sensitization develops, or if the infection persists or worsens, treatment should be discontinued, and appropriate alternative therapy initiated. **4. Neomycin-related Risks**: The neomycin component carries a risk of allergic contact dermatitis. Furthermore, significant systemic absorption of neomycin, particularly from large areas of compromised skin, can lead to ototoxicity (hearing loss) and nephrotoxicity (kidney damage). Patients with existing hearing impairment, renal dysfunction, or those concurrently receiving other ototoxic/nephrotoxic drugs may be at increased risk. This product is strictly for external use and is not indicated for ophthalmic or otic administration.
Clobetasol propionate is a highly potent topical corticosteroid; therefore, treatment should be limited to short durations and restricted to small areas of the body to minimize the risk of systemic absorption.
Prolonged use, application to large surface areas, or use under occlusive dressings can lead to significant systemic effects, including Cushing's syndrome, adrenal suppression, and other corticosteroid-related adverse events.
Pediatric patients are particularly susceptible to systemic toxicity due to a larger skin surface area to body weight ratio.
Avoid application to the face, groin, and axillae, or for diaper dermatitis, due to increased risk of local and systemic side effects.
The neomycin component carries a risk of allergic sensitization and potential cross-sensitization with other aminoglycosides.
If irritation, sensitization, or superinfection develops, discontinue use and institute appropriate therapy.
Use in pregnant or lactating women should only occur if the potential benefit justifies the potential risk to the fetus or infant.
Avoid contact with eyes; rinse thoroughly if accidental contact occurs.

How it Works (Mechanism of Action)

Clobetasol propionate, a highly potent topical corticosteroid, exerts its anti-inflammatory, antipruritic, and vasoconstrictive effects primarily by inducing phospholipase A2 inhibitory proteins, collectively known as lipocortins. These proteins are believed to control the biosynthesis of potent mediators of inflammation, such as prostaglandins and leukotrienes, by inhibiting the release of their common precursor, arachidonic acid, from membrane phospholipids. Neomycin, an aminoglycoside antibiotic, inhibits bacterial protein synthesis by irreversibly binding to the 30S ribosomal subunit of susceptible bacteria. This binding leads to misreading of the mRNA genetic code, resulting in the production of non-functional proteins and subsequent bacterial cell death. It exhibits broad-spectrum activity against many Gram-negative and some Gram-positive bacteria. Nystatin, an antifungal polyene antibiotic, acts by binding to ergosterol, a critical sterol component of the fungal cell membrane. This binding disrupts the integrity of the cell membrane, leading to the formation of pores, increased cellular permeability, and leakage of essential intracellular components, ultimately resulting in fungal cell death. Its activity is primarily against Candida species. This tripartite mechanism allows the product to reduce inflammation, combat bacterial infections, and treat fungal infections concurrently.